CO5700786A2 - Metodos y composiciones para terapia con interferon - Google Patents

Metodos y composiciones para terapia con interferon

Info

Publication number
CO5700786A2
CO5700786A2 CO05131495A CO05131495A CO5700786A2 CO 5700786 A2 CO5700786 A2 CO 5700786A2 CO 05131495 A CO05131495 A CO 05131495A CO 05131495 A CO05131495 A CO 05131495A CO 5700786 A2 CO5700786 A2 CO 5700786A2
Authority
CO
Colombia
Prior art keywords
methods
therapy
compositions
protein
organs
Prior art date
Application number
CO05131495A
Other languages
English (en)
Inventor
Heidrun Engler
Tattanahalli L Nagabhushan
Stephen Youngster
Robert Connor
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/455,215 external-priority patent/US20040014709A1/en
Application filed by Canji Inc filed Critical Canji Inc
Publication of CO5700786A2 publication Critical patent/CO5700786A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1.- Se proveen métodos y composiciones farmacéuticas para administrar terapia de proteínas a tejidos u órganos que tengan una capa celular epitelial. En un aspecto, la terapia con proteína es administrada al tejido u órgano objetivo en combinación con tratamiento con un agente realzador de entrega de terapia con proteína el cual aumenta la transducción de las células de los tejidos u órganos objetivos por el vector. Los métodos y las combinaciones pueden ser útiles para el tratamiento de cánceres y otras condiciones que respondan a la terapia con una proteína biológicamente activa. En realizaciones preferidas, el agente realzador de entrega es SYN3.
CO05131495A 2003-06-04 2005-12-30 Metodos y composiciones para terapia con interferon CO5700786A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47592603P 2003-06-04 2003-06-04
US10/455,215 US20040014709A1 (en) 1996-01-08 2003-06-04 Methods and compositions for interferon therapy

Publications (1)

Publication Number Publication Date
CO5700786A2 true CO5700786A2 (es) 2006-11-30

Family

ID=37064612

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05131495A CO5700786A2 (es) 2003-06-04 2005-12-30 Metodos y composiciones para terapia con interferon

Country Status (6)

Country Link
US (2) US7355056B2 (es)
CN (3) CN1845932A (es)
CO (1) CO5700786A2 (es)
IL (1) IL172294A0 (es)
NZ (1) NZ543970A (es)
ZA (1) ZA200600025B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014709A1 (en) * 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US7002027B1 (en) * 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6392069B2 (en) * 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
SI1456377T1 (sl) * 2001-12-20 2019-09-30 Merck Sharp & Dohme Corp. Sestavki SYN3 in postopki
CN1845932A (zh) * 2003-06-04 2006-10-11 坎基股份有限公司 转染剂
BRPI0417451A (pt) * 2003-12-10 2007-04-10 Canji Inc método de tratar um tumor resistente a interferon
CA2923352C (en) * 2013-09-19 2022-05-03 Crucell Holland B.V. Stable adenovirus formulations
CN104610388B (zh) * 2015-02-09 2017-07-28 上海交通大学 乳糖‑多巴胺分子的合成及含糖聚多巴胺纳米粒子的制备
CN105985386B (zh) * 2015-02-11 2018-06-26 大连民族学院 一类蔗糖酯型阳离子基因载体及其制备方法
IL296520A (en) * 2020-03-19 2022-11-01 Trizell Ltd A virus storage system that responds to temperature

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
IL100240A (en) 1990-12-06 1995-10-31 Hoechst Ag History of bile acids, the process for their preparation and pharmaceutical preparations containing them
JPH06509329A (ja) 1991-06-28 1994-10-20 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 細胞の部位特異的な点滴注入または細胞の部位特異的形質転換による疾患の治療およびそのためのキット
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US5795870A (en) 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
US5260524A (en) * 1992-05-14 1993-11-09 The Coca-Cola Company Muffler for air compressor and method
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
JP3819422B2 (ja) 1993-10-15 2006-09-06 シトリックス コーポレイション 治療用送達組成物及びその使用方法
DE69434594T2 (de) 1993-10-25 2006-09-21 Canji, Inc., San Diego Rekombinante adenoviren-vektor und verfahren zur verwendung
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5552309A (en) 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
US7163925B1 (en) 1995-07-17 2007-01-16 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
AU6600396A (en) 1995-07-28 1997-02-26 David E. Kohne Method for enhancing chemiluminescence
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US20040014709A1 (en) 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
SI1456377T1 (sl) 2001-12-20 2019-09-30 Merck Sharp & Dohme Corp. Sestavki SYN3 in postopki
US20050136035A1 (en) 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
WO2004108088A2 (en) 2003-06-04 2004-12-16 Canji, Inc. Methods and compositions for interferon therapy
CN1845932A (zh) 2003-06-04 2006-10-11 坎基股份有限公司 转染剂
BRPI0417451A (pt) 2003-12-10 2007-04-10 Canji Inc método de tratar um tumor resistente a interferon

Also Published As

Publication number Publication date
US20080234221A1 (en) 2008-09-25
CN1845932A (zh) 2006-10-11
IL172294A0 (en) 2006-04-10
CN101396555A (zh) 2009-04-01
US20050085427A1 (en) 2005-04-21
CN1852918A (zh) 2006-10-25
US7355056B2 (en) 2008-04-08
ZA200600025B (en) 2007-03-28
NZ543970A (en) 2008-09-26
CN100429220C (zh) 2008-10-29

Similar Documents

Publication Publication Date Title
CO5700786A2 (es) Metodos y composiciones para terapia con interferon
CY1119951T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης και αγωγη λοιμωξης hiv
AR040396A1 (es) Citoquinas protectoras de tejidos para la proteccion, restauracion y mejoramiento de celulas, tejidos y organos receptivos
NO20060019L (no) Fremgangsmater og preparater for interferonterapi
ES2190472T3 (es) Parche transdermico para la administracion de 17-deacetil norgestimato, solo o en combinacion con un estrogeno.
BR9910251A (pt) Estimulação hematopoiética
HUP0301405A2 (hu) Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények
WO2005030083A3 (en) Methods and products which utilize n-acyl-l-aspartic acid
WO2008030547B1 (en) Intramyocardial patterning for global cardiac resizing and reshaping
NO20056000L (no) Vevsbeskyttende cytokiner for beskyttelse, gjenoppbygging og okning av responsivceller, vev og organer med et utvidet terapeutisk vindu
CY1116164T1 (el) Προδρομη 4-σουλφαταση ν-ακετυλογαλακτο σαμινης, μεθοδοι θεραπευτικης αγωγης που χρησιμοποιουν το εν λογω ενζυμο και μεθοδοι για παραγωγη και καθαρισμο του εν λογω ενζυμου
BR0209114A (pt) Terapia de combinação usando agentes antiangiogênicos e tnfalfa
BRPI0516265A (pt) composição, uso da mesma, método de aumentar a retenção de um agente terapêutico dentro dos lipossomas, formulação lipossomal, e, uso de um agente terapêutico encapsulado lipossomalmente
Smith et al. Hyaluronidase enhances the therapeutic effect of vinblastine in intralesional treatment of Kaposi's sarcoma
EE200200565A (et) Vaskulaarse kahjustava toimega kombinatsioonravi
OA10698A (en) Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof.
AR048051A1 (es) Composiciones para obtener beneficios en la piel con el uso de intermediarios del metabolismo celular
BRPI0413410A (pt) co-administração de um polissacarìdeo com um agente quimioterapêutico para o tratamento de cáncer
BR0210994A (pt) Compostos farmacêuticos e de diagnósticos contendo nanopartìculas úteis para tratamento de tecidos e células
AR016254A1 (es) Una composicion de celulas de tumor modificadas con un hapteno o extracto de celulas tumorales y uso de la misma en la elaboracion de un medicamento.
ITRM970238A0 (it) Uso del nerve growth factor nella conservazione di cornee in coltura, nella produzione di tessuti corneali e congiuntivali in vitro e nella terapia di patologie corneali e congiuntivali
BR0312365A (pt) Meio de cultura autólogo de células-mães progenitoras autólogas humanas, métodos para a preparação do mesmo e de uma composição de células-mães progenitoras autólogas humanas e para a obtenção de células-mães progenitoras musculares autólogas humanas, emprego de um meio de cultura autólogo de células-mães progenitoras autólogas humanas, procedimento para a obtenção de células-mães progenitoras musculares autólogas humanas e procedimento terapêutico de cardiomioplastia celular autóloga, composição enriquecida com células-mães progenitoras musculares autólogas humanas e composição farmacêutica
MD2849G2 (ro) Metodă de tratament al cancerului mamar la pacientele de vârstă înaintată
WO2005107765A3 (en) Heart treatment method
RU2343901C2 (ru) Активированный вспененный материал (варианты)

Legal Events

Date Code Title Description
FC Application refused